SEC Form 10-Q Summary
Filing identity: The provided filing is for Neuralstem, Inc., not Palisade Bio, Inc. It covers the quarter ended March 31, 2012 and was filed May 9, 2012. Financial statements are unaudited.
Business Context and Reporting Period
Neuralstem was a development-stage biotechnology company focused on human neural stem-cell therapies for central nervous system diseases and small-molecule compounds, including NSI-189 for major depressive disorder. The company had no commercial product revenue and relied primarily on equity financings, warrant exercises, grants, and research contracts.
- At March 31, 2012, the company had 14 full-time employees and two full-time independent contractors.
- Clinical programs included Phase I trials for amyotrophic lateral sclerosis and major depressive disorder.
- The chronic spinal cord injury IND remained on clinical hold.
- The company recognized revenue from a Department of Defense contract performed as a subcontractor to Loma Linda University.
Key Financial Metrics
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $156,250 | $0 |
| Operating expenses | $2,619,466 | $3,536,503 |
| Operating loss | $2,463,216 | $3,536,503 |
| Other income | $10,435 | $434,701 |
| Net loss | $2,452,781 | $3,101,802 |
| Net loss per share | $0.05 | $0.07 |
| Net cash used in operating activities | $2,100,610 | $2,288,448 |
| Net cash used in investing activities | $28,768 | $94,688 |
| Net cash provided by financing activities | $4,921,501 | $1,668,327 |
| Cash and cash equivalents at period-end | $5,144,136 | $8,546,424 |
- Research and development expense was $1.42 million, down 18% year over year.
- General and administrative expense was $1.16 million, down 34% year over year.
- Share-based compensation was approximately $370,000, compared with approximately $1.15 million in Q1 2011.
- Working capital was approximately $3.47 million, and stockholders’ equity was $4.53 million at March 31, 2012.
- Total liabilities were $2.31 million; the filing reports no long-term debt.
- Accumulated deficit was $100.93 million.
Material Changes Versus the Prior Comparable Period
- Revenue increased from zero to $156,250, entirely from the Department of Defense/Loma Linda contract; no product-sale revenue was generated.
- Operating expenses decreased by $917,037, or 26%, primarily because of lower stock-based compensation and reduced patent-litigation expenses.
- Net loss improved by $649,021, although Q1 2011 included $250,000 of lawsuit-settlement income and a $161,809 gain from warrant remeasurement.
- Operating cash use declined by approximately $188,000, or 8%.
- Cash increased during the quarter because of financing, but period-end cash was 40% below the March 31, 2011 balance.
- On February 14, 2012, the company issued 5.2 million shares and 5.2 million warrants, generating net proceeds of approximately $4.92 million.
- Shares outstanding increased to 54.06 million at March 31, 2012 from 48.68 million at December 31, 2011.
Guidance, Outlook, Risks, and Unusual Items
- Management estimated a monthly cash burn rate of approximately $700,000 and expected available cash, anticipated income, and expected financing proceeds to fund current activities through March 31, 2013, potentially requiring reductions in activities or personnel.
- The company stated that it would need significant additional capital and did not expect to become profitable in the next several years.
- A March 2012 term sheet contemplated a private placement of $2 million to $4 million, but completion was uncertain.
- The company expected approximately $78,000 of additional second-quarter 2012 revenue under the Department of Defense contract, subject to contract performance and continuation.
- Management expected to begin dosing patients in the NSI-189 Phase Ib trial during the second quarter of 2012 and sought FDA approval to continue the ALS trial under an amended protocol.
- The Department of Defense program could end after its initial year if options were not exercised.
- Two related patent disputes with StemCells, Inc. remained unresolved. Management believed ordinary litigation would not materially affect financial condition, but the outcome and timing were uncertain.
- Material risks included clinical-trial failure, FDA nonapproval, manufacturing and supplier dependence, intellectual-property disputes, financing availability, dilution, litigation costs, and significant operating losses.
- The CFO resigned effective April 9, 2012. The CEO, I. Richard Garr, became interim CFO and principal accounting officer, with third-party consultants assisting the finance function.
- Management concluded that disclosure controls were effective and reported no material changes to internal control over financial reporting during the quarter.
Investor Verification Priorities
- Verify the filing-company mismatch: the source document is Neuralstem, Inc., while the request identifies Palisade Bio, Inc.
- Confirm the sustainability and terms of future financing, including the proposed $2 million to $4 million placement and potential equity dilution.
- Reconcile the stated $700,000 monthly cash burn with the $5.14 million cash balance and the projected March 31, 2013 funding horizon.
- Track FDA decisions and clinical progress for the ALS and NSI-189 programs, including the spinal cord injury clinical hold.
- Assess continuation of the Department of Defense contract and the reliability of related revenue.
- Monitor the StemCells patent litigation and any resulting licensing costs, restrictions, damages, or operational impact.
- Review the implications of the CFO departure, interim finance leadership, and reliance on third-party reporting consultants.
- Consider dilution from outstanding options, warrants, restricted stock units, and future capital raises.